{"id":48,"count":6,"description":"<div class=\"scroll-box\">\r\n<h2 style=\"text-align: center\">Explorarea Peptidelor GLP-1: Aplica\u021bii de Cercetare \u00een Metabolism \u0219i Reglarea Apetitului<\/h2>\r\n<em>Peptidele GLP-1 reprezint\u0103 o categorie de compu\u0219i de cercetare studia\u021bi pentru efectele lor asupra regl\u0103rii zah\u0103rului din s\u00e2nge, suprim\u0103rii apetitului \u0219i echilibrului metabolic. Aceste peptide imit\u0103 sau sporesc ac\u021biunea peptidului-1 similar glucagonului, un hormon care joac\u0103 un rol central \u00een homeostazia glucozei \u0219i aportul de energie. \u00cen mediusle de laborator, peptidele GLP-1 sunt investigate \u00een mod obi\u0219nuit pentru poten\u021bialul lor \u00een modelele de obezitate, diabet de tip 2 \u0219i gestionare a greut\u0103\u021bii. <\/em>\r\n\r\nGLP-1 peptides are a class of research compounds that mimic or enhance the activity of glucagon-like peptide-1, a hormone involved in appetite control, insulin secretion, and glucose metabolism. In scientific studies, these peptides are explored for their ability to suppress hunger, promote fat loss, and regulate blood sugar levels, making them a major focus in research targeting obesity, type 2 diabetes, and other metabolic disorders.\r\n\r\nGLP-1 receptor agonists work by activating incretin pathways (GLP-1, GIP, and glucagon receptors), which collectively help improve insulin sensitivity, slow gastric emptying, reduce food intake, and increase metabolic expenditure. More advanced compounds in this class also target multiple receptors to enhance metabolic effects, offering new possibilities for studying complex weight-related mechanisms in lab settings.\r\n\r\n<em><strong>Declinarea responsabilit\u0103\u021bii: <\/strong>Toate peptidele GLP-1 men\u021bionate aici sunt destinate exclusiv utiliz\u0103rii \u00een cercetarea de laborator. Orice rezultate legate de oameni men\u021bionate se bazeaz\u0103 exclusiv pe descoperiri din modele animale sau date clinice \u0219i nu trebuie interpretate ca sfaturi medicale sau recomand\u0103ri terapeutice.<\/em>\r\n<h2>Ce sunt peptidele agoni\u0219ti ai receptorilor GLP-1?<\/h2>\r\nGLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. In research settings, GLP-1 is known for its ability to stimulate insulin secretion, suppress appetite, slow gastric emptying, and regulate blood sugar. However, the natural hormone breaks down quickly in the body, prompting the development of longer-lasting analogs for laboratory use.\r\n\r\nModern GLP-1 peptides are engineered for increased stability and often include multi-receptor activity. In addition to GLP-1 activation, some of these peptides also target:\r\n<ul>\r\n \t<li><strong>GIP (Polipeptidul insulinotropic dependent de glucoz\u0103):<\/strong> Stimuleaz\u0103 eliberarea de insulin\u0103 \u0219i influen\u021beaz\u0103 metabolismul gr\u0103similor<\/li>\r\n \t<li><strong>Receptori de glucagon:<\/strong> Promoveaz\u0103 oxidarea gr\u0103similor, termogeneza \u0219i consumul de energie<\/li>\r\n<\/ul>\r\nAceste efecte combinate fac ca agoni\u0219tii receptorilor GLP-1 s\u0103 fie valoro\u0219i \u00een modelele de cercetare preclinic\u0103 axate pe:\r\n<ul>\r\n \t<li>Pierdere \u00een greutate \u0219i supresia apei\u021bii<\/li>\r\n \t<li>Obezitatea \u0219i sindromul metabolic<\/li>\r\n \t<li>Rezisten\u021ba la insulin\u0103 \u0219i homeostazia glucozei<\/li>\r\n \t<li>Studiile privind masa gras\u0103 \u0219i echilibrul energetic<\/li>\r\n<\/ul>\r\nPepsidele precum Semaglutida, Tirzepatida \u0219i Retatrutida sunt utilizate \u00een mod obi\u0219nuit \u00een aceast\u0103 categorie de cercetare pentru efectele lor metabolice puternice \u0219i de reducere a greut\u0103\u021bii.\r\n<h2>Mecanismele de ac\u021biune ale peptidelor GLP-1<\/h2>\r\nGLP-1 receptor agonist peptides work by mimicking or enhancing natural gut hormones that regulate hunger, insulin release, and energy metabolism. Each peptide in this category acts on different combinations of receptors to drive metabolic effects. Here's a breakdown of the mechanisms by individual peptide:\r\n\r\n<strong>Semaglutid\u0103<\/strong>\r\n<ul>\r\n \t<li>Un agonist al receptorului GLP-1, Semaglutida imit\u0103 hormonii incretinici naturali.<\/li>\r\n \t<li>\u00cencetine\u0219te golirea gastric\u0103, prelungind senza\u021bia de sa\u021bietate \u0219i reduc\u00e2nd aportul de calorii.<\/li>\r\n \t<li>Stimuleaz\u0103 secre\u021bia de insulin\u0103 ca r\u0103spuns la glucoz\u0103 \u0219i scade nivelul zah\u0103rului din s\u00e2nge.<\/li>\r\n \t<li>Designul s\u0103u cu ac\u021biune prelungit\u0103 sprijin\u0103 administrarea o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 \u00een modelele de cercetare, men\u021bin\u00e2nd o activare stabil\u0103 a receptorilor \u00een timp.<\/li>\r\n<\/ul>\r\n<strong>Tirzepatid<\/strong>\r\n<ul>\r\n \t<li>Un agonist dual at\u00e2t pentru receptorii GLP-1, c\u00e2t \u0219i pentru cei ai GIP (polipeptid insulinotropic dependent de glucoz\u0103).<\/li>\r\n \t<li>\u00cembun\u0103t\u0103\u021be\u0219te sensibilitatea \u0219i secre\u021bia de insulin\u0103, modul\u00e2nd \u00een acela\u0219i timp nivelurile de glucagon.<\/li>\r\n \t<li>Suprim\u0103 puternic apetitul \u0219i \u00eembun\u0103t\u0103\u021be\u0219te controlul glicemic, duc\u00e2nd la o pierdere remarcabil\u0103 \u00een greutate.<\/li>\r\n \t<li>\u00cen studiile clinice SURPASS, Tirzepatida a dep\u0103\u0219it Semaglutida \u00een reducerea greut\u0103\u021bii corporale \u0219i a glicemiei.<\/li>\r\n<\/ul>\r\n<strong>Retatrutid<\/strong>\r\n<ul>\r\n \t<li>Un agonist cu triplu receptor care are ca \u021bint\u0103 receptorii pentru GLP-1, GIP \u0219i glucagon.<\/li>\r\n \t<li>Activeaz\u0103 c\u0103ile glucagonului pentru a cre\u0219te consumul de energie \u0219i rata metabolic\u0103 bazal\u0103.<\/li>\r\n \t<li>Promoveaz\u0103 lipoliza \u0219i oxidarea gr\u0103similor, fiind unul dintre cei mai poten\u021bi peptide studia\u021bi pentru reducerea gr\u0103simii corporale.<\/li>\r\n \t<li>Primele teste pe oameni arat\u0103 o sc\u0103dere \u00een greutate mai mare dec\u00e2t \u00een cazul altor compu\u0219i pe baz\u0103 de GLP-1.<\/li>\r\n<\/ul>\r\n\u00cempreun\u0103, aceste peptide reprezint\u0103 o clas\u0103 puternic\u0103 de regulatori metabolici \u00een studiile de laborator, oferind o perspectiv\u0103 asupra controlului apetitului, dinamicii insulinei \u0219i echilibrului energetic.\r\n<h2>Cercetare \u0219i descoperiri clinice<\/h2>\r\nPeptidele GLP-1 precum Semaglutid\u0103, Tirzepatid\u0103 \u0219i Retatrutid\u0103 au redefinit cercetarea metabolic\u0103 datorit\u0103 efectelor lor puternice asupra sc\u0103derii \u00een greutate, regl\u0103rii apetitului \u0219i controlului glicemiei. Fiecare a fost studiat \u00een cadrul unor teste clinice \u0219i de laborator ample, cu rezultate constant puternice:\r\n<h3>Semaglutid\u0103<\/h3>\r\n<ul>\r\n \t<li>\u00cen cadrul studiilor clinice STEP, subiec\u021bii obezi f\u0103r\u0103 diabet au pierdut, \u00een medie, ~15% din greutatea corporal\u0103 pe parcursul a 68 de s\u0103pt\u0103m\u00e2ni.<\/li>\r\n \t<li>Reduceri semnificative s-au observat, de asemenea, \u00een ceea ce prive\u0219te circumferin\u021ba taliei, insulina a jeun \u0219i biomarkerii inflamatori.<\/li>\r\n \t<li>Participan\u021bii au raportat suprimarea apetitului \u00een c\u00e2teva zile, \u00eembun\u0103t\u0103\u021bind aderen\u021ba \u00een protocoalele de cercetare pe termen lung.<\/li>\r\n<\/ul>\r\n<h3>Tirzepatid<\/h3>\r\n<ul>\r\n \t<li>Studiul SURMOUNT-1 a demonstrat o sc\u0103dere a greut\u0103\u021bii corporale de aproximativ 22,51 TP3T pe parcursul a 72 de s\u0103pt\u0103m\u00e2ni.<\/li>\r\n \t<li>Tirzepatida a \u00eembun\u0103t\u0103\u021bit, de asemenea, nivelul HbA1c, sensibilitatea la insulin\u0103 \u0219i profilul lipidic.<\/li>\r\n \t<li>Activitatea sa dual\u0103 GIP \u0219i GLP-1 l-a f\u0103cut superior agoni\u0219tilor GLP-1 singuri \u00een studii comparative directe.<\/li>\r\n \t<li>Cercet\u0103rile arat\u0103 beneficii at\u00e2t \u00een modelele metabolice diabetice, c\u00e2t \u0219i \u00een cele nediabetice.<\/li>\r\n<\/ul>\r\n<h3>Retatrutid<\/h3>\r\n<ul>\r\n \t<li>Un studiu de faz\u0103 II (2023) a eviden\u021biat o pierdere \u00een greutate de p\u00e2n\u0103 la 24,21 TP3T la participan\u021bii supraponderali sau obezi, cea mai mare valoare \u00eenregistrat\u0103 p\u00e2n\u0103 \u00een prezent \u00een clasa incretinelor.<\/li>\r\n \t<li>Prin activarea receptorului de glucagon, acesta a crescut consumul de energie \u0219i oxidarea gr\u0103similor dincolo de mecanismele GLP-1\/GIP singure.<\/li>\r\n \t<li>Au fost demonstrate, de asemenea, beneficii \u00een ceea ce prive\u0219te tensiunea arterial\u0103, trigliceridele \u0219i gr\u0103simea hepatic\u0103.<\/li>\r\n<\/ul>\r\n<strong>Informa\u021bii generale de ansamblu<\/strong>\r\n\r\nToate cele trei peptide arat\u0103 \u00een mod constant:\r\n<ul>\r\n \t<li>Suprimarea rapid\u0103 a apetitului<\/li>\r\n \t<li>Mas\u0103 gras\u0103 redus\u0103, circumferin\u021b\u0103 a taliei \u0219i insulin\u0103 a jeun<\/li>\r\n \t<li>Markeri cardiometabolici \u00eembun\u0103t\u0103\u021bi\u021bi (colesterol, tensiune arterial\u0103, CRP)<\/li>\r\n \t<li>Timpii de \u00eenjum\u0103t\u0103\u021bire lungi \u00eei fac ideali pentru administrarea dozelor de cercetare s\u0103pt\u0103m\u00e2nal sau la dou\u0103 s\u0103pt\u0103m\u00e2ni<\/li>\r\n<\/ul>\r\nAceste descoperiri au consolidat agoni\u0219tii receptorilor GLP-1 drept compu\u0219i de baz\u0103 \u00een cercetarea obezit\u0103\u021bii \u0219i a metabolismului.\r\n<h2>Informa\u021bii privind siguran\u021ba \u0219i reglement\u0103rile<\/h2>\r\nGLP-1 peptide research continues to evolve, with several compounds already approved for clinical use and others in advanced trial phases:\r\n\r\nSemaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is widely studied in metabolic models and has a well-documented safety profile in both diabetic and non-diabetic populations.\r\n\r\nTirzepatide, a dual GLP-1\/GIP agonist, is also FDA-approved for type 2 diabetes (as Mounjaro) and is under review for obesity-related approvals, following positive SURMOUNT trial data.\r\n\r\nRetatrutide, the triple agonist (GLP-1, GIP, glucagon), remains investigational but has shown groundbreaking results in Phase II trials, with potential to become a new class leader in fat loss and metabolic support research.\r\n\r\n<strong>Efectele observate frecvent \u00een cercetare includ:<\/strong>\r\n<ul>\r\n \t<li>Grea\u021b\u0103<\/li>\r\n \t<li>Constipa\u021bie<\/li>\r\n \t<li>Sugestionarea apei \/ Inapeten\u021b\u0103 \/ Suprimarea apetitului<\/li>\r\n \t<li>Acestea sunt de obicei dependente de doz\u0103 \u0219i se reduc \u00een timp \u00een studiile de lung\u0103 durat\u0103.<\/li>\r\n<\/ul>\r\n<strong>Instruc\u021biuni de utilizare:<\/strong>\r\n<ul>\r\n \t<li>A se aplica \u00een medii de laborator controlate, axate pe obezitate, rezisten\u021b\u0103 la insulin\u0103 sau metabolismul energetic.<\/li>\r\n \t<li>Men\u021bine\u021bi tehnica steril\u0103, depozitarea \u00een lan\u021b de frig \u0219i documentarea protocolului pentru replicabilitate.<\/li>\r\n<\/ul>\r\n<strong>Memento important:<\/strong>\r\n\r\nToate peptidele discutate sunt destinate exclusiv utiliz\u0103rii \u00een cercetarea de laborator. Ele nu sunt aprobate pentru administrare la umane dec\u00e2t \u00een contextul unor studii clinice reglementate sau pe baz\u0103 de re\u021bet\u0103.\r\n<h2>Cele mai bune peptide GLP-1 pentru cercetare<\/h2>\r\nPeptidele GLP-1 au revolu\u021bionat cercetarea \u00een domeniul metabolic \u0219i al obezit\u0103\u021bii. Urm\u0103toarele peptide se remarc\u0103 prin eficacitatea lor bine documentat\u0103 \u00een modelele preclinice \u0219i clinice:\r\n<ul>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/ro\/product\/buy-semaglutide-5mg\/\"><strong>Semaglutid\u0103<\/strong><\/a> \u2013 Un agonist al receptorului GLP-1, care a f\u0103cut obiectul unor numeroase studii, cunoscut pentru rolul s\u0103u \u00een suprimarea apetitului, reglarea glicemiei \u0219i reducerea masei grase. \u00cen studiile pe termen lung privind obezitatea, acesta a demonstrat o sc\u0103dere constant\u0103 a greut\u0103\u021bii corporale de aproximativ 15%.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/ro\/product\/buy-tirzepatide-5mg\/\"><strong>Tirzepatid<\/strong><\/a> \u2013 Un agonist dual GLP-1\/GIP care \u00eembun\u0103t\u0103\u021be\u0219te sensibilitatea la insulin\u0103 \u0219i reduce greutatea corporal\u0103 chiar mai eficient dec\u00e2t semaglutida. Studiile clinice precum SURMOUNT-1 au raportat o pierdere medie \u00een greutate de 22,5% la subiec\u021bii trata\u021bi.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/ro\/product\/buy-retatrutide-5mg\/\"><strong>Retatrutid<\/strong><\/a> \u2013 Un agonist triplu de nou\u0103 genera\u021bie care ac\u021bioneaz\u0103 asupra receptorilor GLP-1, GIP \u0219i glucagon. Studiile clinice ini\u021biale indic\u0103 o pierdere de gr\u0103sime de p\u00e2n\u0103 la 24,2%, ceea ce \u00eel face unul dintre cele mai puternice peptide din cercetarea actual\u0103 privind obezitatea.<\/li>\r\n<\/ul>\r\n<h2>Utilizare de laborator \u0219i reconstituire<\/h2>\r\nPeptidele GLP-1 precum Semaglutide, Tirzepatide \u0219i Retatrutide trebuie reconstituite corespunz\u0103tor \u0219i manipulate \u00een condi\u021bii sterile de laborator pentru a men\u021bine stabilitatea \u0219i acurate\u021bea \u00een cercetare.\r\n\r\n<strong>Reconstituire<\/strong>Majoritatea peptidevei GLP-1 pot fi reconstituite folosind ap\u0103 bacteriostatic\u0103 sau solu\u021bie salin\u0103 steril\u0103. Injecta\u021bi lent solventul pe peretele interior al flaconului pentru a evita formarea de spum\u0103 \u0219i agita\u021bi u\u0219or p\u00e2n\u0103 la dizolvarea complet\u0103.\r\n\r\n<strong>Stocare<\/strong>:\r\n<ul>\r\n \t<li>Peptidele liofilizate pot fi depozitate la temperatura camerei \u0219i ferite de lumin\u0103.<\/li>\r\n \t<li>Peptidele reconstituite r\u0103m\u00e2n stabile timp de 30-60+ zile atunci c\u00e2nd sunt refrigerate la 2\u20138 \u00b0C.<\/li>\r\n<\/ul>\r\n<strong>Administrarea dozelor \u00een modele preclinice:<\/strong>\r\n\r\nDoza standard variaz\u0103 de la 0,01\u20130,2 mg\/kg la \u0219oareci sau \u0219obolani, \u00een func\u021bie de configura\u021bia experimental\u0103 \u0219i de obiectivele cercet\u0103rii.\r\n<h3>Puncte Finale Comune de Cercetare:<\/h3>\r\n<ul>\r\n \t<li>Monitorizarea greut\u0103\u021bii corporale \u00een timp<\/li>\r\n \t<li>Inhibarea apetitului \u0219i monitorizarea aportului de alimente<\/li>\r\n \t<li>Teste de toleran\u021b\u0103 la glucoz\u0103 (TTG)<\/li>\r\n \t<li>Analiza masei \u0219i a compozi\u021biei \u021besutului adipos<\/li>\r\n \t<li>Activitatea hormonilor incretinici, inclusiv testele pentru insulin\u0103, GLP-1, GIP \u0219i glucagon<\/li>\r\n<\/ul>\r\nAce\u0219ti peptide sunt destina\u021bi exclusiv cercet\u0103rii de laborator, iar toat\u0103 manipularea trebuie s\u0103 respecte protocoalele etice \u0219i cele mai bune practici sterile.\r\n<h2>\u00centreb\u0103ri frecvente<\/h2>\r\n<h3>Care peptid\u0103 GLP-1 produce cea mai mare sc\u0103dere \u00een greutate?<\/h3>\r\nRetatrutida a demonstrat cea mai semnificativ\u0103 sc\u0103dere \u00een greutate (~24%) \u00een studiile clinice ini\u021biale.\r\n<h3>Pot peptidele fi combinate pentru rezultate mai bune?<\/h3>\r\nDe obicei, nu. Retatrutida activeaz\u0103 deja receptorii GLP-1, GIP \u0219i glucagon, f\u0103c\u00e2nd inutil\u0103 asocierea suplimentar\u0103.\r\n<h3>Ce ar trebui s\u0103 fac dac\u0103 un peptid\u0103 nu se dizolv\u0103 complet?<\/h3>\r\nAgita\u021bi u\u0219or flaconul prin mi\u0219c\u0103ri circulare, nu-l agita\u021bi prin asv\u00e2rlire. O u\u0219or \u00eenc\u0103lzire (\u00eentr-o baie de ap\u0103 la 37\u00b0C) poate ajuta la dizolvare.\r\n<h3>Exist\u0103 diferen\u021be \u00een ceea ce prive\u0219te afinitatea pentru receptori \u00eentre aceste peptide?<\/h3>\r\nYes. Semaglutide selectively targets GLP-1 receptors, while Tirzepatide and Retatrutide act on multiple receptors for a broader effect.\r\n\r\nTo finish up, GLP-1 peptides represent a leading edge in metabolic research, offering compelling avenues to study fat loss, insulin regulation, and appetite suppression. Peptides such as Semaglutide, Tirzepatide, and Retatrutide have shown significant effects in both preclinical and clinical models, making them valuable tools for obesity and diabetes-related investigations.\r\n\r\nExplore the full GLP-1 peptide catalog at CellPeptides to support your next metabolic research project.\r\n\r\n<\/div>","link":"https:\/\/cellpeptides.com\/ro\/purpose\/glp-1-peptides\/","name":"Peptide de cercetare GLP-1","slug":"glp-1-peptides","taxonomy":"product_cat","parent":0,"meta":[],"menu_order":0,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/ro\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/ro\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"CollectionPage\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"url\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"name\":\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"description\":\"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\"},\"inLanguage\":\"ro-RO\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cump\u0103r\u0103 peptide GLP-1 pentru studii metabolice (In-vitro) - CellPeptides","description":"Cump\u0103ra\u021bi agoni\u0219ti ai receptorilor GLP-1 pentru cercetarea apetitului, a glucozei \u0219i a metabolismului - Semaglutid\u0103, Tirzepatid\u0103, Retatrutid\u0103. Livrare rapid\u0103 \u00een SUA \u0219i UE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/ro\/purpose\/glp-1-peptides\/","og_locale":"ro_RO","og_type":"article","og_title":"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides","og_description":"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU","og_url":"https:\/\/cellpeptides.com\/ro\/purpose\/glp-1-peptides\/","og_site_name":"CellPeptides","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"CollectionPage","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","url":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","name":"Cump\u0103r\u0103 peptide GLP-1 pentru studii metabolice (In-vitro) - CellPeptides","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"description":"Cump\u0103ra\u021bi agoni\u0219ti ai receptorilor GLP-1 pentru cercetarea apetitului, a glucozei \u0219i a metabolismului - Semaglutid\u0103, Tirzepatid\u0103, Retatrutid\u0103. Livrare rapid\u0103 \u00een SUA \u0219i UE","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb"},"inLanguage":"ro-RO"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"CellPeptides","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ro-RO"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"CellPeptides","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/ro\/wp-json\/wp\/v2\/product_cat\/48","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/ro\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/cellpeptides.com\/ro\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"wp:post_type":[{"href":"https:\/\/cellpeptides.com\/ro\/wp-json\/wp\/v2\/product?product_cat=48"}],"curies":[{"name":"Bine jucat","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}